Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2026	Apr. 30, 2025	Apr. 30, 2026	Apr. 30, 2025	Oct. 31, 2025
Segment Reporting [Line Items]
Revenues
Research and development expenses	1,258	1,322	2,360	2,874
General and administrative expenses	1,389	1,681	3,003	3,515
Total operating expenses	2,647	3,003	5,363	6,389
Loss from operations	(2,647)	(3,003)	(5,363)	(6,389)
Interest income	111	190	242	363
Net loss	(2,536)	(2,813)	(5,121)	(6,026)
Total operating expenses	2,647	3,003	5,363	6,389
Less non-cash stock-based compensation	(665)	(988)	(1,461)	(2,043)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	1,982	2,015	3,902	4,346
Total assets	14,865		14,865		$ 16,080
Cancer Vaccines [Member]
Segment Reporting [Line Items]
Revenues
Research and development expenses	812	898	1,485	1,873
General and administrative expenses	898	1,109	1,888	2,262
Total operating expenses	1,710	2,007	3,373	4,135
Loss from operations	(1,710)	(2,007)	(3,373)	(4,135)
Interest income	72	128	152	237
Net loss	(1,638)	(1,879)	(3,221)	(3,898)
Total operating expenses	1,710	2,007	3,373	4,135
Less non-cash stock-based compensation	(421)	(643)	(908)	(1,304)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	1,289	1,364	2,465	2,831
Total assets	9,626		9,626		9,604
CAR-T Therapeutics [Member]
Segment Reporting [Line Items]
Revenues
Research and development expenses	446	424	875	1,001
General and administrative expenses	480	562	1,101	1,224
Total operating expenses	926	986	1,976	2,225
Loss from operations	(926)	(986)	(1,976)	(2,225)
Interest income	38	61	89	124
Net loss	(888)	(925)	(1,887)	(2,101)
Total operating expenses	926	986	1,976	2,225
Less non-cash stock-based compensation	(243)	(343)	(551)	(734)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	683	643	1,425	1,491
Total assets	5,139		5,139		6,347
Other [Member]
Segment Reporting [Line Items]
Revenues
Research and development expenses
General and administrative expenses	11	10	14	29
Total operating expenses	11	10	14	29
Loss from operations	(11)	(10)	(14)	(29)
Interest income	1	1	1	2
Net loss	(10)	(9)	(13)	(27)
Total operating expenses	11	10	14	29
Less non-cash stock-based compensation	(1)	(2)	(2)	(5)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	10	$ 8	12	$ 24
Total assets	$ 100		$ 100		$ 129